Alto Neuroscience reported total assets of $254.07M and total liabilities of $34.82M for the quarter ended Jun 2026, up 60.9% year over year. This balance sheet covers 14 quarters of results from Mar 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||
| Current Assets | ||||||||||||||
| Cash & EquivalentsCash & Equiv. | 82.55M | 205.90M | 193.12M | 181.70M | 168.23M | 160.75M | 147.59M | 137.82M | 176.48M | 263.76M | 243.73M | |||
| Receivables - OtherOther Receivables | 0.04M | -0.07M | -0.29M | 0.01M | -0.01M | |||||||||
| Prepaid Assets | 2.84M | 2.42M | 2.29M | 1.82M | 1.11M | 2.77M | 2.26M | 1.63M | 1.23M | 5.36M | 3.59M | |||
| Current Assets | 85.39M | 208.31M | 195.41M | 183.53M | 169.34M | 163.52M | 149.85M | 139.45M | 177.72M | 269.13M | 247.32M | |||
| Non-Current Assets | ||||||||||||||
| Property, Plant & Equipment (Net) | 1.11M | 1.55M | 1.44M | 2.35M | 2.67M | 2.48M | 2.31M | 2.03M | 1.87M | 2.23M | 2.05M | |||
| Other Non-Current Assets | 0.13M | 0.06M | 0.50M | 0.50M | 0.50M | 0.57M | 0.57M | 0.57M | 0.50M | 0.50M | 0.50M | |||
| Non-Current Assets | 1.24M | 1.61M | 1.95M | 8.08M | 8.21M | 8.39M | 8.03M | 7.56M | 6.97M | 7.13M | 6.75M | |||
| Assets | 86.63M | 209.92M | 197.36M | 191.61M | 177.54M | 171.91M | 157.88M | 147.01M | 184.69M | 276.26M | 254.07M | |||
| Liabilities | ||||||||||||||
| Current Liabilities | ||||||||||||||
| Accounts Payables | 1.07M | 2.41M | 1.84M | 2.25M | 1.58M | 1.38M | 1.67M | 2.06M | 1.88M | 3.37M | 4.02M | |||
| Payables | 1.07M | 2.41M | 1.84M | 2.25M | 1.58M | 1.38M | 1.67M | 2.06M | 1.88M | 3.37M | 4.02M | |||
| Accumulated Expenses | 4.54M | 4.45M | 5.68M | 8.23M | 8.43M | 5.87M | 6.46M | 6.99M | 8.86M | 7.61M | 8.86M | |||
| Short term Debt | 1.15M | 2.32M | 3.53M | 0.58M | 2.14M | 3.77M | ||||||||
| Total Current Liabilities | 5.61M | 8.01M | 9.84M | 14.02M | 10.01M | 7.26M | 8.13M | 9.04M | 11.32M | 13.12M | 16.65M | |||
| Non-Current Liabilities | ||||||||||||||
| Non-Current Debt | 9.86M | 9.96M | 10.06M | 10.16M | 10.25M | 19.94M | 20.12M | 20.31M | 16.17M | 13.88M | 12.42M | |||
| Convertible Debt | 1.30M | 1.30M | 1.21M | 2.00M | 2.12M | 2.23M | 2.33M | 2.46M | ||||||
| Preferred Stock Liabilities | 97.08M | 97.08M | 97.08M | 141.48M | ||||||||||
| Operating Leases | 0.12M | 5.20M | 5.39M | 4.41M | 4.21M | 3.97M | 3.82M | 3.56M | 3.28M | |||||
| Other Non-Current Liabilities | 1.70M | 1.60M | 1.40M | 1.35M | ||||||||||
| Total Non-Current Liabilities | 43.52M | 51.00M | 59.70M | 15.47M | 16.82M | 17.58M | 26.56M | 26.08M | ||||||
| Total Liabilities | 45.23M | 52.60M | 61.10M | 16.82M | 16.82M | 17.58M | 26.56M | 26.08M | 32.82M | 34.47M | 35.45M | 33.55M | 32.89M | 34.82M |
| Shareholder's Equity | ||||||||||||||
| Total Debt | 9.86M | 11.11M | 12.38M | 13.69M | 10.25M | 19.94M | 20.12M | 20.31M | 16.76M | 16.02M | 16.19M | |||
| Common Equity | -45.23M | -52.60M | -61.10M | -71.67M | 193.10M | 179.78M | 165.05M | 151.46M | 139.10M | 123.41M | 111.56M | 151.14M | 243.37M | 219.25M |
| Liabilities and Shareholders Equity | 86.63M | 209.92M | 197.36M | 191.61M | 177.54M | 171.91M | 157.88M | 147.01M | 184.69M | 276.26M | 254.07M | |||
| Retained Earnings | -76.97M | 283.57M | 286.27M | 288.34M | 289.95M | 292.64M | 294.65M | 296.99M | 352.75M | 471.22M | 474.74M | |||
| Treasury Shares | 20.37M | 20.37M | 20.37M | 29.92M |